van der Sijde R, de Bruijn H W, Krans M, Bouma J, Aalders J G
Department of Obstetrics and Gynecology, University Hospital, Groningen, The Netherlands.
Gynecol Oncol. 1989 Nov;35(2):227-32. doi: 10.1016/0090-8258(89)90049-8.
The significance of serum SCC antigen as a tumor marker was investigated in 94 women with squamous cell carcinoma of the vulva. The incidence of elevated serum SCC levels varied from 10% in FIGO stage I to 40% in FIGO stage IV. We did not observe a correlation between elevated pretreatment SCC values and the presence of lymph node metastases. During follow-up, elevated serum SCC values were observed in 8 of 19 patients (42%) with recurrent or progressive disease. It is concluded that the determination of serum SCC levels does not provide additional information in the staging of squamous cell vulvar carcinoma, but can be useful for the early detection of recurrent disease during follow-up in some patients. However, elevated serum SCC levels were also found in 25% of patients without demonstrable tumor activity during follow-up and benign skin disorders were recognized as a cause of false-positive SCC results.
对94例外阴鳞状细胞癌女性患者血清鳞状细胞癌抗原作为肿瘤标志物的意义进行了研究。血清鳞状细胞癌水平升高的发生率在国际妇产科联盟（FIGO）I期为10%，在FIGO IV期为40%。我们未观察到术前鳞状细胞癌值升高与淋巴结转移之间存在相关性。在随访期间，19例复发或病情进展患者中有8例（42%）血清鳞状细胞癌值升高。结论是，血清鳞状细胞癌水平的测定在外阴鳞状细胞癌分期中并未提供额外信息，但在随访期间对一些患者复发性疾病的早期检测可能有用。然而，在随访期间无明显肿瘤活动的患者中，25%也发现血清鳞状细胞癌水平升高，良性皮肤疾病被认为是鳞状细胞癌假阳性结果的一个原因。
